Why Ultragenyx Pharmaceutical Stock Is Bouncing Back Today [Yahoo! Finance]
Ultragenyx Pharmaceutical Inc. (RARE)
Last ultragenyx pharmaceutical inc. earnings: 2/13 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.ultragenyx.com/investor-relations
Company Research
Source: Yahoo! Finance
Ultragenyx reported yesterday that two Phase 3 studies failed to achieve primary endpoints for setrusumab. Despite the Wells Fargo analyst's positive outlook, Ultragenyx stock should only remain a consideration for those comfortable with more speculative investments. 10 stocks we like better than Ultragenyx Pharmaceutical › While Ultragenyx Pharmaceutical (NASDAQ: RARE) provided the market with disappointing news yesterday -- shares plunged more than 42% -- it appears that investors aren't completely writing off the company's potential as a developer of treatments for rare diseases. A firm's favorable view of Ultragenyx stock is motivating some investors to click the buy button today, helping the stock recover from its recent decline. As of 2:51 p.m. ET, shares of Ultragenyx are up 13.2%. Maintaining an overweight rating Wells Fargo analyst Benjamin Burnett reduced the price target on Ultragenyx stock to $45 from $65 today. According to TheFly.com , Burnett informed inves
Show less
Read more
Impact Snapshot
Event Time:
RARE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RARE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RARE alerts
High impacting Ultragenyx Pharmaceutical Inc. news events
Weekly update
A roundup of the hottest topics
RARE
News
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RAREPR Newswire
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RAREGlobeNewswire
- Is It Time To Reconsider Ultragenyx Pharmaceutical (RARE) After A 39.1% One Year Decline? [Yahoo! Finance]Yahoo! Finance
- A Look At Ultragenyx Pharmaceutical (RARE) Valuation After Revenue Beat And Gene Therapy Catalysts Update [Yahoo! Finance]Yahoo! Finance
- Morgan Stanley Trims Ultragenyx (RARE) PT to $50 While Betting on 2026 Biotech Recovery [Yahoo! Finance]Yahoo! Finance
RARE
Earnings
- 11/4/25 - Miss
RARE
Sec Filings
- 1/12/26 - Form 8-K
- 1/5/26 - Form 4
- 1/2/26 - Form 144
- RARE's page on the SEC website